Art

J-GLOBAL ID：202102285121509098   Reference number：21A0084115

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

EGFR-変異非小細胞肺癌におけるEGFR-TKIの治療有効性を予測する同時遺伝子変異と他のバイオマーカー: レビュー【JST・京大機械翻訳】

Author (10)： Guo Yijia (Department of Clinical Oncology, Shengjing Hospital of China Medical University, Shenyang, China) ,  Song Jun (Department of Clinical Oncology, Shengjing Hospital of China Medical University, Shenyang, China) ,  Wang Yanru (Department of Clinical Oncology, Shengjing Hospital of China Medical University, Shenyang, China) ,  Huang Letian (Department of Clinical Oncology, Shengjing Hospital of China Medical University, Shenyang, China) ,  Sun Li (Department of Clinical Oncology, Shengjing Hospital of China Medical University, Shenyang, China) ,  Zhao Jianzhu (Department of Clinical Oncology, Shengjing Hospital of China Medical University, Shenyang, China) ,  Zhang Shuling (Department of Clinical Oncology, Shengjing Hospital of China Medical University, Shenyang, China) ,  Jing Wei (Department of Clinical Oncology, Shengjing Hospital of China Medical University, Shenyang, China) ,  Ma Jietao (Department of Clinical Oncology, Shengjing Hospital of China Medical University, Shenyang, China) ,  Han Chengbo (Department of Clinical Oncology, Shengjing Hospital of China Medical University, Shenyang, China)
Material： Frontiers in Oncology (Web)
Volume： 10  Page： 610923  Publication year： 2020 
JST Material Number： U7089A  ISSN： 2234-943X  Document type： Article
Article type： 文献レビュー  Country of issue： Switzerland (CHE)  Language： ENGLISH (EN)

Abstract/Point： Epidermal growth factor recept...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=21A0084115&from=J-GLOBAL&jstjournalNo=U7089A") }}

Thesaurus term： optimization ,  *heredity ,  *gene ,  genome ,  therapeutic planning ,  *non-small cell lung cancer ,  *EGF receptor ,  *biomarker ,  *genetic variation
Semi thesaurus term： K-Ras ,  PTEN ,  TP53 ,  臨床医 ,  *EGFRチロシンキナーゼ阻害剤 ,  PIK3CA , 【Automatic Indexing@JST】

Author keywords (5)： non-small cell lung cancer ,  concurrent genetic alteration ,  epidermal growth factor receptor tyrosine kinase inhibitors ,  PD-L1 expression ,  BIM polymorphism

JST classification (3)： Tumors(=neoplasms)of respiratory system  (GI04000G) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Clinical application of antitumor(=antineoplastic)drugs  (GW16020L)

Reference (176)：

• BrayFFerlayJSoerjomataramISiegelRLTorreLAJemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2018) 68:394-424. doi: doi: 10.3322/caac.21492
• ChengLAlexanderREMaclennanGTCummingsOWMontironiRLopez-BeltranA. Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol (2012) 25:347-69. doi: doi: 10.1038/modpathol.2011.215
• YangCYYangJCYangPC. Precision Management of Advanced Non-Small Cell Lung Cancer. Annu Rev Med (2020) 71:117-36. doi: doi: 10.1146/annurev-med-051718-013524
• MaemondoMInoueAKobayashiKSugawaraSOizumiSIsobeH. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med (2010) 362:2380-8. doi: doi: 10.1056/NEJMoa0909530
• MitsudomiTMoritaSYatabeYNegoroSOkamotoITsurutaniJ. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol (2010) 11:121-8. doi: doi: 10.1016/S1470-2045(09)70364-X

Terms in the title (7)： 変異 ,  非小細胞肺癌 ,  治療有効性 ,  予測 ,  遺伝子変異 ,  バイオマーカー ,  レビュー